IGHE and allergic asthma: In an RCT [41] performed on patients with mild allergic asthma, the anti-IgE mAb rhuMAb-E25 (later named omalizumab) delivered at a dose of 0.5 mg/kg for nine visits did not significantly improve the provocative concentration of methacholine causing a 20% FEV1 (PC20) compared to PBO.